Following the Appraisal Committee meeting on this for ‘Beta interferons and glatiramer acetate for treating multiple sclerosis [ID809]’ on 23 May, we are pausing this appraisal.
From discussions with the companies we understand that several are considering access agreements for their technologies, which means that the basis for the decision making is likely to change. NICE is committed to working towards a solution that ensures patients with multiple sclerosis continue to have access to beta-interferons and glatiramer acetate. We therefore do not consider it appropriate to release an ACD at this stage. We will provide an update on the future timelines as soon as we can.